Circulating immune checkpoints predict heart failure outcomes

Circulating immune checkpoints predict heart failure outcomes

Abstract Aims There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). Methods and results Transcriptomic an...

Detaylı Bibliyografya
Asıl Yazarlar:	Elles M. Screever, Laura I.E. Yousif, Javid J. Moslehi, Joe‐Elie Salem, Adriaan A. Voors, Herman H.W. Silljé, Rudolf A. deBoer, Wouter C. Meijers
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	Wiley 2023-08-01
Seri Bilgileri:	ESC Heart Failure
Konular:	Immune checkpoints PD‐L1 PD‐L2 Galectin‐9 Heart failure
Online Erişim:	https://doi.org/10.1002/ehf2.14304

Benzer Materyaller

Expression patterns of immune checkpoints in acute myeloid leukemia
Yazar:: Cunte Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2020-04-01)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Yazar:: Douglas B. Johnson, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Yazar:: Federica Costa, ve diğerleri
Baskı/Yayın Bilgisi: (2018-09-01)

The role of immune checkpoints in cardiovascular disease
Yazar:: Laura I. Yousif, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Enhancing cancer care with improved checkpoint inhibitors
Yazar:: Vickram A S, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
Yazar:: Ruby Dhar, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
Yazar:: Kazuhiko Hashimoto, ve diğerleri
Baskı/Yayın Bilgisi: (2020-07-01)

Immune Checkpoint in Glioblastoma: Promising and Challenging
Yazar:: Jing Huang, ve diğerleri
Baskı/Yayın Bilgisi: (2017-05-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Yazar:: Juwon Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Yazar:: Ruiting Li, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
Yazar:: Sai Mummareddy, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yazar:: Tianrui Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Yazar:: Jan Willem Kleinovink, ve diğerleri
Baskı/Yayın Bilgisi: (2017-04-01)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Yazar:: Xin Cai, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression
Yazar:: Sebastian Marwitz, ve diğerleri
Baskı/Yayın Bilgisi: (2017-05-01)

Immune Checkpoint Inhibitors in Cancer Therapy
Yazar:: Yavar Shiravand, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Immune Checkpoints and Innovative Therapies in Glioblastoma
Yazar:: Massimo Romani, ve diğerleri
Baskı/Yayın Bilgisi: (2018-10-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
Yazar:: YU Lin, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

The Role of Immune Checkpoint Inhibitors in Cancer Therapy
Yazar:: Ahmed M. Basudan
Baskı/Yayın Bilgisi: (2022-12-01)

The role of immune checkpoint inhibitors in prostate cancer
Yazar:: Gabriel Surdacki, ve diğerleri
Baskı/Yayın Bilgisi: (2019-03-01)

Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases
Yazar:: Andreas von Knethen, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
Yazar:: Alberto Bongiovanni, ve diğerleri
Baskı/Yayın Bilgisi: (2021-05-01)

Immune checkpoint blockade therapy for bladder cancer treatment
Yazar:: Jayoung Kim
Baskı/Yayın Bilgisi: (2016-06-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Yazar:: Ya Xu, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
Yazar:: Edyta Zyla, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers
Yazar:: Emily Hensler, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Key questions about the checkpoint blockade-are microRNAs an answer?
Yazar:: Mihnea Dragomir, ve diğerleri
Baskı/Yayın Bilgisi: (2018-06-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Yazar:: Maria Georganaki, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
Yazar:: William L. Redmond, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Yazar:: Reid P. Bissonnette, ve diğerleri
Baskı/Yayın Bilgisi: (2021-08-01)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
Yazar:: Ji Won Han, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
Yazar:: Kübra KAHVECİ, ve diğerleri
Baskı/Yayın Bilgisi: (2019-12-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
Yazar:: Zachary S. Buchwald, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
Yazar:: Amjad Zafar, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
Yazar:: Myrna G. Garcia, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
Yazar:: Jiaxin Zhou, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Yazar:: Adel Naimi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
Yazar:: Zhanjun Guo, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Profiling targetable immune checkpoints in osteosarcoma
Yazar:: Troy A McEachron, ve diğerleri
Baskı/Yayın Bilgisi: (2018-12-01)

The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges
Yazar:: Deniz Can Guven, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)